Autor: |
William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D’Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain, Souhir Neffati, Jean-Yves Pierga, Francois-Clement Bidard |
Jazyk: |
angličtina |
Rok vydání: |
2019 |
Předmět: |
|
Zdroj: |
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019) |
Druh dokumentu: |
article |
ISSN: |
1465-542X |
DOI: |
10.1186/s13058-019-1215-z |
Popis: |
Abstract Background In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC. Methods Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥ 2 prior lines of chemotherapy and measurable disease. CTC with a HER2/CEP17 ratio of ≥ 2.2 by fluorescent in situ hybridization (CellSearch) were considered to be HER2-amplified (HER2 amp ). Patients with ≥ 1 HER2 amp CTC were eligible for the treatment phase (T-DM1 monotherapy). The primary endpoint was the overall response rate. Results In 154 screened patients, ≥ 1 and ≥ 5 CTC/7.5 ml of blood were detected in N = 118 (78.7%) and N = 86 (57.3%) patients, respectively. ≥1 HER2 amp CTC was found in 14 patients (9.1% of patients with ≥ 1 CTC/7.5 ml). Among 11 patients treated with T-DM1, one achieved a confirmed partial response. Four patients had a stable disease as best response. Median PFS was 4.8 months while median OS was 9.5 months. Conclusions CTC with HER2 amplification can be detected in a limited subset of HER2-negative MBC patients. Treatment with T-DM1 achieved a partial response in only one patient. Trial registration NCT01975142, Registered 03 November 2013 |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|